RPG Life Sciences Ltd
RPG Life Sciences Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on RPG Life Sciences Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Revenue from Operations for Q3 FY26 was Rs. Q3 FY26 Financials vs Q3 FY25 (Page 14): - EBITDA: ₹180.0 Cr (Q3 FY26) vs ₹172.7 Cr (Q3 FY25) - EBITDA Margin: 24.0% (Q3 FY26) vs 30.4% (Q3 FY25) → significant margin contraction - PBT: ₹43.2 Cr (Q3 FY26) vs ₹52.5 Cr (Q3 FY25) - PBT Margin: 15.5% (Q3 FY26) vs 20.9% (Q3 FY25) → decline in profit before tax margin - PAT: ₹27.9 Cr (Q3 FY26) vs ₹34.8 Cr (Q3 FY25) - PAT Margin: 15.5% (Q3 FY26) vs 20.2% (Q3 FY25) → notable decrease in net profit margin - Year-on-Year Change: EBITDA up marginally by ~4.2%; margins and profits declined significantly.
From RPG Life Sciences Ltd's Q3 FY26 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Revenue from Operations for Q3 FY26 was Rs. 180.0 crore, up from Rs. 172.7 crore in Q3 FY25 (+4.2% YoY). (Page 14)
- EBITDA for Q3 FY26 was Rs. 43.2 crore, down from Rs. 52.5 crore in Q3 FY25 (-17.7% YoY). (Page 14)
- PBT for Q3 FY26 was Rs. 37.5 crore, down from Rs. 46.9 crore in Q3 FY25 (-20.0% YoY). (Page 14)
- PAT for Q3 FY26 was Rs. 27.9 crore, down from Rs. 34.8 crore in Q3 FY25 (-19.8% YoY). (Page 14)
- Domestic Formulations contributed 71% to total sales in Q3 FY26, International Formulations 18%, APIs 11%. (Page 16)
- Domestic Formulations grew: sales Rs. 100.2 crore vs. Rs. 94.4 crore in 9M FY25 (+6.1%). (Page 16)
2 more points management made on revenue & sales performance
Profitability & Margins
See what RPG Life Sciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Since FY22, Rs. 140 crores capex infused for building a modern plant with approvals from EU, TGA, PMDA, and others. (Page 27)
- Modernization and capacity expansion underway for Formulations Units 1 and 2 at Ankleshwar. (Page 24)
- MF2 (Dedicated immunosuppressant facility), MF3, and MF4 multipurpose units are all undergoing modernization and capacity expansion; approvals include WHO GMP, TGA (Australia), PMDA (Japan), etc. (Page 24)
- State-of-the-art manufacturing capacity operating EU/TGA-approved plant with enhanced capacity for quality and compliance. (Page 22)
- Business transformation includes multiple infrastructure modernization and capacity expansion projects targeted at improving quality and manufacturing productivity. (Page 10, 9)
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what RPG Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
RPG Life Sciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹177 Cr, net profit ₹30 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What RPG Life Sciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharmaceuticals Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27] . Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Morepen Laboratories Ltd (Q3 FY26)
488 crores, up 17% from Q3 FY25 Rs. Key concall takeaways from Morepen Laboratories Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q3 FY26)
2,143 Cr., up from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- NGL Fine Chem Ltd (Q3 FY26)
Quarterly Revenue (Q3FY26):** ₹127.51 crores . Key concall takeaways from NGL Fine Chem Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were RPG Life Sciences Ltd Q3 FY26 results?
Revenue from Operations for Q3 FY26 was Rs. Q3 FY26 Financials vs Q3 FY25 (Page 14): - EBITDA: ₹180.0 Cr (Q3 FY26) vs ₹172.7 Cr (Q3 FY25) - EBITDA Margin: 24.0% (Q3 FY26) vs 30.4% (Q3 FY25) → significant margin contraction - PBT: ₹43.2 Cr (Q3 FY26) vs ₹52.5 Cr (Q3 FY25) - PBT Margin: 15.5% (Q3 FY26) vs 20.9% (Q3 FY25) → decline in profit before tax margin - PAT: ₹27.9 Cr (Q3 FY26) vs ₹34.8 Cr (Q3 FY25) - PAT Margin: 15.5% (Q3 FY26) vs 20.2% (Q3 FY25) → notable decrease in net profit margin - Year-on-Year Change: EBITDA up marginally by ~4.2%; margins and profits declined significantly.
What is RPG Life Sciences Ltd share price analysis?
RPG Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 39.7 with a market cap of ₹4,635 Cr. Investors should review the full earnings analysis for detailed insights.
Is RPG Life Sciences Ltd planning capital expenditure?
Since FY22, Rs.
Keep RPG Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.